Less than a tenth of patients that would benefit from GLP-1 drugs such as Wegovy can access them, states the global health agency as it issues its initial guidance on the medications.
Considering in excess of 1,000,000,000 individuals worldwide currently obese, it is urging broader and more equitable access to these injectable treatments.
Per projections, in excess of 2,000,000,000 are projected to be obese by 2030 without intervention.
"Our new guidelines acknowledges that excess weight is a chronic disease that can be treated with holistic and lifelong support," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and supply-chain constraints are key hurdles to broad access to the injections that can aid individuals in losing significant weight, notes the body.
Skinny Jab Scarcity
Even in the present best projected case, the manufacturing of such drugs might only reach around 100 million people – less than 10% of those who need them, as stated by the health organization.
The guideline calls on nations and manufacturers to widen access, via strategies including patent sharing.
The intellectual property rights on a key compound – the primary component of a leading brand – is set to lapse in multiple nations in 2026.
The Way Obesity Injections Work
These medications replicate a biological compound to reduce digestion speed, curb appetite and enhance feelings of fullness so users consume fewer calories.
Patients commonly see weight reduction within a few weeks of starting on the weekly injections.
Evidence indicates people may see weight return after a year of halting the drug, as their normal hunger resume.
To be carrying excess weight raises your chance for experiencing health problems, including diabetes, cardiovascular issues, brain attack, and some cancers.
Obesity affects people in all nations and was associated with millions of deaths worldwide in 2024, according to the WHO.
